BridgeBio Pharma (BBIO) EBIAT: 2019-2025
Historic EBIAT for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$184.9 million.
- BridgeBio Pharma's EBIAT fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$805.7 million, marking a year-over-year decrease of 80.53%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
- Latest data reveals that BridgeBio Pharma reported EBIAT of -$184.9 million as of Q3 2025, which was down 0.64% from -$183.8 million recorded in Q2 2025.
- BridgeBio Pharma's EBIAT's 5-year high stood at -$2.6 million during Q2 2022, with a 5-year trough of -$267.4 million in Q4 2024.
- Moreover, its 3-year median value for EBIAT was -$169.6 million (2025), whereas its average is -$157.7 million.
- In the last 5 years, BridgeBio Pharma's EBIAT spiked by 97.49% in 2022 and then tumbled by 6,179.91% in 2023.
- Quarterly analysis of 5 years shows BridgeBio Pharma's EBIAT stood at -$152.3 million in 2021, then climbed by 7.69% to -$140.6 million in 2022, then declined by 21.17% to -$170.3 million in 2023, then slumped by 56.98% to -$267.4 million in 2024, then decreased by 12.59% to -$184.9 million in 2025.
- Its EBIAT stands at -$184.9 million for Q3 2025, versus -$183.8 million for Q2 2025 and -$169.6 million for Q1 2025.